| Trial ID: | L3568 |
| Source ID: | NCT03580967
|
| Associated Drug: |
Vortioxetine
|
| Title: |
Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2 Diabetes|Major Depressive Disorder
|
| Interventions: |
DRUG: Vortioxetine
|
| Outcome Measures: |
Primary: Change in depressive symptoms measured by Hamilton Depression Rating Scale (HAM-D), The HAM-D is an 18-item questionnaire used to provide an indication of depression. The patient is rated by a clinician on 18 items scored on a 3-point or 5-point Likert-type scale. Remission of Major Depressive Disorder symptoms is defined as a total score on the HAM-D of ≤ 7., Baseline and End of Treatment visit (Week 8) |
|
| Sponsor/Collaborators: |
Sponsor: Todd Doyle | Collaborators: Takeda
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2019-07-01
|
| Completion Date: |
2021-07-01
|
| Results First Posted: |
|
| Last Update Posted: |
2022-11-29
|
| Locations: |
Loyola University Medical Center, Maywood, Illinois, 60153, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03580967
|
